@article{discovery10192138, number = {5}, month = {May}, journal = {British Journal of Haematology}, publisher = {WILEY}, title = {Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis}, year = {2024}, note = {This version is the author-accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions.}, volume = {204}, pages = {1811--1815}, author = {Khwaja, Jahanzaib and Bomsztyk, Joshua and Atta, Maria and Bygrave, Ceri and Forbes, Adam and Durairaj, Senthil and Fernandes, Savio and Taylor, James and Paterson, Pamela and Brearton, Gillian and Crawley, Charles and Sheehy, Oonagh and Brown, Rachel and Soutar, Richard and Garg, Mamta and Rydzewski, Andrzej and Jamroziak, Krzysztof and Mahmood, Shameem and Wechalekar, Ashutosh D}, issn = {0007-1048}, abstract = {Systemic light chain (AL) amyloidosis is a relapsing plasma cell disorder. Therapy is limited, particularly for triple-class refractory disease. We report the use of belantamab mafodotin, a BCMA-directed drug-antibody conjugate, for relapsed AL amyloidosis, including patients traditionally excluded from clinical trials. Thirty-one patients were reviewed, with a median of three prior lines of therapy. The median follow-up was 12 months (95\% CI 4-19), and a median of five doses were delivered. The best haematological overall response rate was 71\%, and the complete/very good partial response was 58\%. Sixty-eight percent had keratopathy and improved in all. Belantamab mafodotin has high efficacy and good tolerability in patients with relapsed AL amyloidosis.}, url = {https://doi.org/10.1111/bjh.19286}, keywords = {amyloidosis, antibody therapy, immunotherapy} }